and re-suspended in IMDM medium containing 5% pooled, heat-inactivated human serum (PHS; Australian Red Cross, Melbourne, Australia), 100 mM non-essential amino acids, 2 mM glutamine and 50 μM 2-mercaptoethanol (IP5 medium).
Bioactivity of HMGB1. PBMCs cells (2x10
5 /well) were cultured in IP5 medium and THP-1 cells (2x10 5 /well) in RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum (Sigma-Aldrich, St. Louis, Mo), in 96-well plates. Cells were stimulated with 50 ng/ml ultrapure E. coli LPS or 2 µg/ml Pam3CSK4 (Invivogen, San Diego, Calif) in the presence and absence of two different recombinant HMGB1 isoforms, HMGB1-disulfide or HMGB1-3S (HMGBiotech, Milan, Italy). HMGB1-disulfide pre-treated with DTT (1mM) for 2 hours was also included as a second negative control for HMGB1-disulfide. -- -- 
